SCHEMBL4610271

SCHEMBL4610271

CCc1n[nH]c(CC)c1Cc1ccc(C#N)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.47
KCNH2 Q12809 4/20 0.47
LOXL2 Q9Y4K0 2/20 0.41
HRH3 Q9Y5N1 1/20 0.40
GHSR Q92847 1/20 0.39
AR P10275 1/20 0.38
SLC5A1 P13866 2/20 0.38
SLC5A2 P31639 2/20 0.38
PGR P06401 1/20 0.36
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
P2RX7 Q99572 1/20 0.34
KCNJ1 P48048 1/20 0.34
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5751664 0.85 KCNH2 (0.57) CYP2A6KCNH2GHSRSLC5A1SLC5A2
SCHEMBL12803437 0.84 CYP2A6 (0.46) CYP2A6KCNH2LOXL2HRH3GHSR
SCHEMBL6419682 0.80 NPC1 (0.39) KCNH2HRH3SLC5A1SLC5A2P2RX7
SCHEMBL4109180 0.72 KCNH2 (0.75) CYP2A6KCNH2PGRCYP19A1
SCHEMBL4240032 0.72 AR (0.59) LOXL2ARP2RX7
SCHEMBL7118321 0.69 P2RX7 (0.39) KCNH2HSD17B10P2RX7
SCHEMBL91062 0.67 CYP2A6 (1.00) CYP2A6KCNH2LOXL2TSHRHSD17B10
SCHEMBL1344068 0.67 LOXL2 (0.65) CYP2A6KCNH2LOXL2HRH3SAE1
SCHEMBL694505 0.66 PARP1 (0.45) LOXL2HRH3AR
SCHEMBL7402930 0.65 MEN1 (0.53) LOXL2HRH3ARSAE1UBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425569-B2 1H-pyrazoles useful in therapy PFIZER INC (US) 2008-09-16 US disclosed
US-7425569-B2 1H-pyrazoles useful in therapy PFIZER INC (US) 2008-09-16 US disclosed
US-7425569-B2 1H-pyrazoles useful in therapy PFIZER INC (US) 2008-09-16 US disclosed
EP-1948615-A2 COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2008-07-30 EP disclosed
US-20080085919-A1 1H-Pyrazoles Useful In Therapy BRADLEY PAUL A 2008-04-10 US disclosed
US-20080085919-A1 1H-Pyrazoles Useful In Therapy BRADLEY PAUL A 2008-04-10 US disclosed
US-20080085919-A1 1H-Pyrazoles Useful In Therapy BRADLEY PAUL A 2008-04-10 US disclosed
US-7309712-B2 1H-pyrazoles useful in therapy PFIZER LIMITED (GB) 2007-12-18 US disclosed
US-7309712-B2 1H-pyrazoles useful in therapy PFIZER LIMITED (GB) 2007-12-18 US disclosed
US-7309712-B2 1H-pyrazoles useful in therapy PFIZER LIMITED (GB) 2007-12-18 US disclosed
WO-2007054770-A2 PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE PFIZER LIMITED (GB) 2007-05-18 WO disclosed
US-20070105909-A1 Compounds useful in therapy PFIZER INC. 2007-05-10 US disclosed
US-20070105909-A1 Compounds useful in therapy PFIZER INC. 2007-05-10 US disclosed
US-20070105909-A1 Compounds useful in therapy PFIZER INC. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105909-A1 Compounds useful in therapy GNRHR, OPRK1, CBR3 CYP2A6 473/4885KCNH2 378/4885LOXL2 2674/4885
US-20080085919-A1 1H-Pyrazoles Useful In Therapy CBR3, GNRHR, RXFP3 CYP2A6 699/4885KCNH2 262/4885LOXL2 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.